| Name | Title | Contact Details |
|---|---|---|
Pierre Gravier |
Chief Financial Officer | Profile |
Steve DeMarco |
Director Pre-clinical R&D, Gene Therapy | Profile |
Laurie Sokol |
Senior Director R&D Finance | Profile |
Ida Licata |
Executive Director FP&A - R&D | Profile |
Tom Hernandez |
Sr. Director - R&D FP&A | Profile |
Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world`s first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Triple-Negative Breast Cancer, Melanoma and Colorectal Cancer.
Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.
Vivace Therapeutics is a venture-backed, oncology-focused portfolio-based drug discovery and development company, based in San Mateo, California. Its programs include both small molecule programs targeting the YAP pathway, and bi-specific programs.
Oxford Instruments PLC is a Carteret, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.